In the prospective WSG TP-II phase II trial (NCT03272477), 207 patients with centrally confirmed HR+/HER2+ early breast cancer were randomized to 12 weeks of standard ET (n = 100) versus paclitaxel 80 mg/m2 weekly (n = 107) plus trastuzumab and pertuzumab intravenously every 3 weeks; all patients received dual HER2-antibody blockade in the adjuvant setting. The gene discussed is HR; the disease is breast carcinoma.